drugset / Trial / NCT00468689
Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.
RandomizedSingle-groupSingle-blindTreatment
Summary
This study will evaluate the safety, tolerability and exposure of SB-751689 when administered alone at supratherapeutic doses and when SB-751689 is co administered with ketoconazole, a PGP/CYP3A4 inhibitor that increases exposure of SB-751689. Data from this study will enable the planning and conduct of a QTc study for SB-751689.
Timeline
- Start
- 2007-04
- Primary completion
- 2007-08
- Completion
- 2007-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketoconazole | Small molecule | 200 mg | Oral |
| Subject | SB-751689 | Unknown | 100 ng | Oral |
| Subject | SB-751689 | Unknown | 400 ng | Oral |